Maximilian Woisetschlaeger

Title: Maximilian Woisetschlaeger: Innovator in Antibody Formulations

Introduction

Maximilian Woisetschlaeger is a notable inventor based in Oberwil, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antibody formulations. With a total of 2 patents, his work focuses on enhancing the efficacy and delivery of therapeutic antibodies.

Latest Patents

Woisetschlaeger's latest patents include innovative formulations of Anti-BAFFR antibodies. These antibodies are designed to be formulated as either a lyophilisate or a liquid formulation. The lyophilisates can be reconstituted to create a solution with a high concentration of the antibody active ingredient, allowing for effective delivery to patients while minimizing antibody aggregation. The aqueous pharmaceutical composition may also include various components such as sugars, buffering agents, surfactants, and free amino acids. Another significant patent involves the method of manufacturing bispecific antibodies, which relates to bivalent bispecific monoclonal antibodies (bbmAb) and their therapeutic applications. This invention outlines methods for co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines.

Career Highlights

Woisetschlaeger is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to contribute to groundbreaking research and development in the field of antibody therapies.

Collaborations

Throughout his career, Woisetschlaeger has collaborated with esteemed colleagues, including Michael Otto Bardroff and Tina Buch. These collaborations have further enriched his research and innovation efforts.

Conclusion

Maximilian Woisetschlaeger stands out as an influential inventor in the biotechnology sector, particularly in the realm of antibody formulations. His patents reflect a commitment to advancing therapeutic solutions for patients.